Preface

This book explores distinct aspects of protein purification and characterization steps.

Chapter 1, "Structure- and Design-Based Difficulties in Recombinant Protein Purification in Bacterial Expression", focuses on issues that are not addressed in straightforward purification processes, such as if the peptide tends to form aggregates and displays solubility problems. It also discusses strategies for small peptide chromatography. The chapter provides solutions for solubility and aggregation problems, such as a unique column and resin selection trick. The proper selection of purification parameters helps the purification process.

Chapter 2, "Protein Detection in Clinical Diagnosis and Management of Prevalent Neurodegenerative Diseases and Metabolic Disorders", examines protein-related diseases and the diagnosis of proteinopathy-related diseases considering the structure and function of the proteins through their deficiencies and overexpression. It also discusses the pathogenesis and the principles underlying the diagnosis of these disorders.

Chapter 3, "Methods of Protein Detection in Cancer for Diagnosis, Prognosis and Therapy", highlights enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, western blot, mass spectrometry, protein microarray, and microfluidics techniques for screening, protein profiling, identification, and qualitative and quantitative analysis of differential expressed oncoproteins at different stages of cancer.

Chapter 4, "Multiple and Single Reaction Monitoring Mass Spectrometry for Absolute Quantitation of Proteins", further elaborates on omic technology. It discusses the technology behind mass spectroscopy-based clinical protein assays in diagnostic and prognostic settings.

Finally, Chapter 5, "Interrelation between Recurrent Pregnancy Loss and Antiphospholipid: A Clinico-Diagnostic Perspective", discusses the role of antiphospholipid in recurrent pregnancy loss from a clinical-diagnostic perspective. Although the most common cause of recurrent pregnancy loss is a cytogenetic anomaly, antiphospholipid antibody, and metabolic and hormonal disorders, half of the cases of recurrent pregnancy loss remain unexplored.

> **Yusuf Tutar** Hamidiye Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences, Division of Biochemistry, University of Health Sciences-Turkey, Istanbul, Turkey

> > **Lütfi Tutar** Kırşehir Ahi Evran University, Kırşehir, Turkey

Section 1
